The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
yong yu ren lei mian yi que xian bing du ji xiang guan gan ran de xin yao
Author(s): 
Pages: 224-225
Year: Issue:  4
Journal: World Clinical Drugs

Keyword:  商品名齐多夫定奈维蛋白酶抑制剂两性霉素利托那韦临床试验逆转录酶抑制剂核苷类似物不良反应;
Abstract: 在美国已有4个新药可用于人类免疫缺陷病毒及其并发症。经美国食物及药品管理局批准的是奈维平(nevirapine,商品名Viramune,Roxane公司)、静注cidofovir(商品名Vistide,Gilead公司)和两性霉素B口服悬液(Fungizone口服悬液,Bristol-MyersSquibb公司)。另一个药物nelfinavir(商品名Viracept,Agouron公司)目前仅能按“扩大试用程序(ExpandedAccessProgram)供应。1奈维平(evirapine)核苷类似物和齐多夫定(AZT,商品名Retrovir)、去羟肌苷(didanosine,ddi,商品名
Related Articles
No related articles found